FOR HEALTH PROVIDERS
Clinical Genomics that fits the way you work
Your patient relationship, with our clinical engine behind it.
You offer whole genome sequencing as part of your clinic’s premium proposition. We provide the sequencing, analysis, and reports. and your team delivers the consultation.
We partner with health providers of every kind, from boutique private clinics to specialist cardiac units to large hospital systems. We adapt to your workflow, your patients, and your clinical requirements. You don’t need to fit around us.
StoreGene’s Clinical Genomic Operating System makes it faster, cheaper and easier to apply whole genome data into actionable clinical insights
Why work with us?
Thorough Consenting
We take consent seriously. Our processes are designed to meet clinical and regulatory standards, and we can adapt consent frameworks to suit your patient population and service model.
Fast Turnaround
We understand that clinical timelines matter. We are transparent about turnaround times upfront and work to meet them consistently, keeping your clinical workflow predictable.
Simple Reanalysis
Because we retain the whole genome, requesting a new analysis or rerunning a previous one is straightforward. No new sample, no new sequencing run. Just a request and a report
Bespoke Assessments
If a standard assessment does not match a clinical question, we can design an analysis around it. We work with clinicians to understand exactly what they need and configure the analysis accordingly.
Clinical-grade Reporting
Our reports are written for clinicians. Clear, structured, and actionable. We flag variants with appropriate classification and evidence grading, and we do not overstate findings.
Flexible Depth
We can adjust the stringency of our variant filtering to match the clinical question. See the section below on adjustable variant thresholds for how this works in practice.
Versatile by design
Our standard reporting applies established evidence thresholds. We report pathogenic and likely pathogenic variants only, keeping reports clean and actionable for general clinical use.
For clinicians pursuing a specific clinical question, such as searching for a known disease mechanism, a particular gene of interest, or an atypical presentation with a suspected genetic cause, we can lower that threshold deliberately. This means including variants of uncertain significance (VUS) in the output, allowing your team to cross-reference against current literature and emerging research.
“StoreGene consistently delivers a truly outstanding level of service, with clear, responsive communication and personalised, dedicated support from the Executive team from Day 1, which has continued throughout. The team has made changes to the delivery format of the report based on our company’s specific requirements; this is a level of service which has fully surpassed our expectations. All queries are responded to swiftly, either by email or with the offering of a Zoom consultation to ensure our needs are fully understood and met. This reliability, combined with competitive pricing and the ability to continuously re-analyse whole genome data as knowledge evolves, makes StoreGene a partner we expect to work with for the long term”
“The Clinical Genomic Operating System will transform translational genetic medicine from geneticists to clinicians.”
Targeted Analysis
We support the use of any virtual gene panel available on PanelApp, allowing clinically curated panels to be applied flexibly to existing or newly sequenced patients. Because analysis is performed on whole-genome data, panels can be run or re-run at any time without the need for additional sequencing, enabling you to adapt testing as clinical questions evolve or new evidence emerges.
Metabolic Disorders
Musculoskeletal
Neurology
Ophthalmology
Rare Disease
Urology
Rapid Turnaround Time
From sample extraction to analysis and finished report, our Whole Genome Sequencing process can be carried out in just 30 days. For reanalysis, this is reduced to just 7 days.
Increased Diagnostic Yield
Over a large number of studies, the diagnostic yield attained by WES ranges between 25 and 50%, while the WGS diagnostic yield is about 40–60%.
Medication management
99.7% of people have a genetic variation which alters how they metabolise common medications. By using pharmacogenomic data you can reduce adverse drug reactions by 30%.
